RxDoctor Payments Data

Amy Reynolds, DO

Family Medicine · Hollsopple, PANPI 1942293360

Payments from drug & device makers

$9,508in general payments, 2019–2025

Across 644 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$923
  • Pfizer$878
  • GSK$848
  • Lilly USA, LLC$769
  • Amarin Pharma, Inc.$645
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$9,488100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,508 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$757
Medicare patients
15
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban432$319,950
JardianceEmpagliflozin298$218,858
OzempicSemaglutide204$217,148
TrulicityDulaglutide142$149,955
TradjentaLinagliptin138$94,250
ProliaDenosumab48$80,800
XareltoRivaroxaban89$76,377
Trelegy ElliptaFluticasone/Umeclidin/Vilanter119$76,256
MounjaroTirzepatide69$74,760
Repatha SureclickEvolocumab99$63,689
JanuviaSitagliptin Phosphate56$56,530
LinzessLinaclotide71$54,379
AbrysvoRsv Vacc, Pref A And Pref B/Pf116$37,541
Breo ElliptaFluticasone/Vilanterol89$35,465
RybelsusSemaglutide27$25,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$878$357,492548 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$295$320,528451 claims
Novo NordiskOzempic, Rybelsus$1,163$242,626231 claims
Lilly USA, LLCTrulicity, Mounjaro$769$224,715211 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$848$136,382254 claims
AmgenProlia$494$80,80048 claims
Johnson & JohnsonXarelto$464$76,37789 claims
MerckJanuvia$448$56,53056 claims
AbbVieLinzess$923$54,37971 claims
NovartisEntresto$215$17,66916 claims
Astellas Pharma US IncMyrbetriq$215$15,80428 claims
AstraZenecaBrilinta$551$10,64516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Hollsopple

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →